ДБДина Дамировна Байдильдина

Дина Дамировна Байдильдина

*This is an algorithmically generated author record based on publicly available information.

Дина Дамировна Байдильдина has a total of 157 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A clinical case of myelodysplastic syndrome with monosomy 7 in a patient with a mutation in the SAMD9L gene

    by E. L. Rashitova, V. A. Bankole, D. D. Baydildina, Э. Л. Рашитова, В. А. Банколе, Д. Д. Байдильдина

    Conditions associated with defects in the SAMD9 and SAMD9L genes are a group of nosologies with a range of clinical symptoms from multisystem lesions in the framework of MIRAGE syndrome to isolated hematological manifestations. The article presents a clinical case of a patient with myelodysplastic syndrome and a germline mutation in the SAMD9L gene. Patient V. developed first symptoms of her illness at the age of 1 year 1 month. She was hospitalized with complaints of a hemorrhagic rash and fever; the hemogram showed isolated thrombocytopenia. A diagnosis of immune thrombocytopenia was established. Given the lack of effect from the first-line therapy, the diagnosis was revised to aplastic anemia. Spontaneous restoration of hematopoiesis was observed 8 days later. At the age of 1 year 5 months, thrombocytopenia and neutropenia were observed. At the age of 2 years, she was initially hospitalized at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and was diagnosed with myelodysplastic syndrome, monosomy 7. The only curative treatment for the disease is allogeneic hematopoietic stem cell transplantation (HSCT). Based on the results of wholegenome sequencing, a germline de novo missense mutation in the SAMD9L gene (“gain-of-function”) was detected. At 2 years and 10 months, the patient was readmitted to the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Transformation into acute leukemia was ruled out, and allogeneic HSCT was performed from a related haploidentical donor. A follow-up examination within the 30th day showed that the graft was functioning satisfactorily, with blasts less than 5% in the myelogram and no signs of dyspoiesis. Conditions associated with mutations in the SAMD9 / SAMD9L genes are rare. Timely diagnosis and prompt HSCT can improve survival rates and reduce the risk of long-term complications.

  • EFFICACY OF VEMURAFENIB COMBINED WITH CYTARABINE AND 2-CHLORO-2′-DEOXYADENOSINE AS FIRST-LINE THERAPY IN CHILDREN WITH MULTISYSTEM LANGERHANS CELL HISTIOCYTOSIS

    by E.A. Burtsev, D.A. Evseev, D.S. Osipova, G.Z. Seregin, D.D. Baydildina, I.I. Kalinina, E.V. Kumirova, A.A. Maschan, M.A. Maschan

    Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder of childhood, driven by pathological activation of the MAPK signaling pathway. The multisystem form with riskorgan involvement (RO+) carries the worst prognosis. BRAF inhibitors show high initial efficacy, but monotherapy is associated with a high reactivation rate after discontinuation, underscoring the need to optimize first-line therapy. Objective: To evaluate the efficacy and tolerability of a combined protocol of vemurafenib with reduced-dose cytarabine (ARA-C) and 2-chloro-2′-deoxyadenosine (2-CdA) as first-line therapy in children with BRAF-positive multisystem LCH. Materials and Methods: A retrospective two-center observational study. Children with BRAF+ multisystem LCH (RO+ and RO–) treated with the protocol as first-line therapy in 2022–2025 were included. The protocol comprised 4 courses of vemurafenib (20 mg/kg/day) alternating with blocks of ARA-C (200 mg/m2/day) and 2-CdA (6 mg/m2/day) at reduced doses; total duration 196 days. Disease activity was assessed with the Disease Activity Score (DAS); complete response (non-active disease, NAD) was defined as 0 points. Event-free survival (EFS) was estimated by the Kaplan–Meier method; the Wilcoxon signed-rank test was used to compare DAS before and after treatment. Results: Twenty patients were enrolled (RO+, n=16; RO–, n=4). In the RO+ group, median age was 9 (1–22) months and median DAS 13 (5–16). NAD was achieved in all 20 (100%) patients, most by the first assessment point. Five-year EFS in the RO+ group was 75%. Reactivation occurred in 3/16 RO+ and 1/4 RO– patients; re-initiation of targeted therapy was effective in all cases. No grade III–IV toxicity (CTCAE v5.0) or disease progression was observed. A decline in BRAF-V600E allelic burden was seen in all 8 evaluated patients. Conclusion: First-line vemurafenib combined with reduced-dose ARA-C/2-CdA achieves NAD in all patients with low organ toxicity and may be considered an alternative to existing first-line regimens in children with multisystem LCH, both RO+ and RO–.

  • Open Access

    Interim results of a multicenter study of treatment of patients with acute myeloid leukemia according to the AML-MRD-2018 protocol

    by G. A. Novichkova, A. V. Popa, Z. A. Abashidze, M. S. Vasilyeva, O. V. Aleinikova, I. I. Kalinina, D. A. Venyov, S. A. Lebedeva, V. A. Bankole, D. D. Baydildina, et al.

    Introduction. Acute myeloid leukemia (AML) is the second most prevalent type of blood malignancy in children that accounts for 15–20% of all pediatric leukemia cases. Before 2018, large-scale prospective studies of AML in children in the Russian Federation were constrained by the absence of both a central pathology review system and centralized monitoring of minimal residual disease (MRD). To address these issues, the national protocol AML-MRD-2018 (NCT03846362) was developed and initiated by the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Materials and methods. This study included 631 patients from 54 clinical facilities across 48 regions of the Russian Federation. Central pathology review was performed at two institutions: the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (Moscow) and Yekaterinburg Regional Children's Clinical Hospital. Risk group stratification was performed in two steps: initially it was based on molecular and genetic characteristics of blast cells, and then (for intermediate risk group) – on response to treatment assessed by MRD testing. Criteria for primary refractoriness and the transfer of patients to a high-risk group were blast cell count (assessed morphologically and immunophenotypically) 5% after induction and MRD ≥ 0.1% after the first course of consolidation. The final stratification was as follows: 67 standard-risk patients, 251 intermediate-risk patients, and 313 high-risk patients. Results. Response to induction therapy was assessable in 580 patients; complete remission was achieved in 84.3% of the cases (n = 489). Treatment effectiveness varied significantly across the risk groups: it was 100% in the standard-risk group (all the patients achieved MRD-negative remission), 91.5% in the intermediate-risk group and 72.9% in the high-risk group (which had the highest proprotion of refractory and MRD positive patients). The first cycle of consolidation therapy according to the protocol was given to 385 patients from the intermediate- and high-risk groups; MRD assessment was performed in 348 cases. MRD-negative remission was achieved in 196 (96%) out of 204 MRD-assessed patients in the intermediate-risk group and in 129 (90%) out of 144 MRD-assessed patients in the high-risk group. The 3-year treatment outcomes in the whole cohort of patients (n = 631) were the following: the overall survival (OS) reached 71% (95% confidence interval (CI) 68–76), the event-free survival (EFS) was 44% (95% CI 40–48), the cumulative risk of relapse (CRR) was 36% (95% CI 31–41). There were significant differences in these parameters between the risk-groups: standard-risk group (n = 67): OS – 84%, EFS – 66%, CRR – 24%; intermediate-risk group (n = 251): OS – 77%, EFS – 50%, CRR – 38%; high-risk group (n = 313): OS – 64%, EFS – 34%, CRR – 37%. Over the period of observation, a total of 255 allogeneic hematopoietic stem cell transplantations (HSCT) were performed. The most common HSCTs were from haploidentical related donors (n = 180; 70%), the graft sources were peripheral blood stem cells (n = 138) and bone marrow (n = 87). The median time from start of therapy to HSCT was 5 months. The 2-year EFS after HSCT was 65% and the 2-year OS post-HSCT was 75%. Conclusion. To date, the potential of universal chemotherapy protocols for AML has been exhausted. Further improvements in treatment outcomes are only possible through the implementation of individualized treatment strategies based on molecular genetic profiling. Promising approaches include the addition of FLT3 inhibitors, gemtuzumab ozogamicin, venetoclax; the inclusion of menin inhibitors in leukemias with KMT2A rearrangements; the integration of hypomethylating agents in the treatment of patients with CBF-AML.

  • Open Access

    Combination treatment for resistant and refractory immune thrombocytopenia in children: a literature review and seven clinical cases

    by Elena V. Suntsova, D. D. Baydildina, Lili A. Khachatryan, M. N. Sadovskaya, V. E. Matveev, D. A. Venyov, V. A. Bankole, Zalina A. Abashidze, Galina A. Novichkova, Alexey A. Maschan, et al.

    Introduction. Immune thrombocytopenia (ITP) is characterized by increased platelet destruction and suboptimal platelet production, which results in reduced platelet counts in peripheral blood and bleeding of varying severity. In children with ITP, remission is often achieved with first-line therapy or even spontaneously. Thrombopoietin receptor agonists and rituximab are considered modern therapies of choice in severe and/or chronic course of the disease, splenectomy is performed less frequently. Despite the favorable prognosis, some patients may exhibit resistance to initial therapy and a small proportion of patients fail to respond to several courses of first- and/or second-line ITP-directed therapies, thus developing refractory ITP. The management of patients with resistant and refractory ITP is a clinical challenge. Clinical cases. The article presents seven clinical cases of severe ITP of varying duration. The patients aged 1.5 to 17 years received combination therapy due to unsatisfactory therapeutic response in order to prevent severe hemorrhagic complications. The article describes the clinical presentation and different therapeutic approaches, discusses modern possibilities and combined treatment regimens for resistant and refractory ITP in children. Conclusion. Overall, current studies of pathogenesis and the development of guidelines for managing ITP patients aim to optimize treatment, particularly for resistant, refractory, severe persistent and chronic forms of the disease, reduce the risk of bleeding, increase the likelihood of achieving long-term remission, and improve the quality of life of patients and their families.

  • Open Access

    Alpha/beta-T-cell depleted hematopoietic stem cell transplantation from unrelated and haploidentical donors in children with idiopathic aplastic anemia

    by Daria A. Shasheleva, L. N. Shelikhova, Maria A. Ilyushina, Rimma D. Khismatullina, A. A. Bogoyavlenskaya, Svetlana A. Radygina, E. E. Kurnikova, Dmitry E. Pershin, Dmitry N. Balashov, O. V. Goronkova, et al.

    Introduction. Hematopoietic stem cell transplantation (HSCT) from an alternative donor is the main treatment option for patients with severe acquired aplastic anemia (AAA) refractory to combined immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A. Although the outcomes of unrelated and haploidentical HSCTs have improved over the years, graft-versus-host disease (GVHD) continues to pose a major clinical challenge associated with significant morbidity and mortality. Aim: to present the outcomes of unrelated and haploidentical HSCTs with TCRαβ-depleted grafts in patients with AAA. Materials and methods. Eighty patients (42 males and 38 females) with AAA underwent HSCT between September 2012 and February 2022. The median age at transplantation was 10 (2.3–22.7) years. Seventy-eight patients received HSCT after relapse or refractory disease after one (n = 14) or two (n = 18) courses of immunosuppressive therapy. Two patients underwent HSCT as first-line treatment. The median time from diagnosis to transplantation was 1 (0.1–11.8) year. Conditioning regimen included cyclophosphamide (100–150 mg/kg), fludarabine (150 mg/kg), antithymocyte globulin (ATGAM (100 mg/kg) or thymoglobulin (5–10 mg/kg)), and thoracoabdominal irradiation (2–6 Gy). In some cases, additional medications such as melphalan (140 mg/m2), thiophosphamide (5–10 mg/kg), and rituximab (200 mg/m2) were used. Patients with paroxysmal nocturnal hemoglobinuria (n = 6) received eculizumab at a dose of 600 mg from day –7 to day +14 (every 7 days). Post-transplant GVHD prophylaxis included calcineurin inhibitors. TCRαβ/CD19 depletion was performed using a CliniMACS Plus system (Miltenyi Biotec, Bergish Gladbach, Germany). The median CD34+ cell dose in the graft was 10 (2.7–23.0) × 10⁶/kg, and the median TCRαβ+ cell dose was 26.6 (0.85–316.00) × 10³/kg. Results. The cumulative incidence of engraftment was 0,95 (95% confidence interval (CI) 0.9–1.0) with the median time to neutrophil recovery being 13 (9–24) days and to platelet recovery – 12 (7–25) days. Graft rejection occurred in 9 patients, the cumulative incidence of rejection was 0,11 (95% CI 0.06–0.20). Three of these patients underwent successful retransplantation. The cumulative incidence of grade II–III acute GVHD was 0,12 (95% CI 0.05–0.27) in the patients who had undergone unrelated donor HSCT versus 0,42 (95% CI 0.29–0.61) in the haploidentical HSCT recipients (p = 0.003). The cumulative incidence of chronic GVHD was 0,5 (95% CI 0.01–0.20) in the unrelated donor HSCT group and 0,21 (95% CI 0.12–0.38) in the haploidentical HSCT group (p = 0.02). The median follow-up was 6.4 years. Twenty-two (27.5%) patients died. Sixteen of them died of complications after the first HSCT; 4 deaths occurred due to complications associated with repeat HSCT. Two patients died after graft rejection due to infectious complications. The overall survival was 0,79 (95% CI 66–91) in the unrelated donor HSCT group and 0,66 (95% CI 51–81) in the haploidentical donor HSCT group. Conclusion. The use of TCRαβ/CD19-depleted HSCT from alternative donors ensured high engraftment rates and reduced the incidence of severe GVHD. However, there were no significant improvements in graft rejection or mortality.

  • Open Access

    Preliminary results of treatment of intermediate-risk patients according to the AML-MRD-2018 protocol

    by M. S. Vasilyeva, I. I. Kalinina, D. A. Venyov, S. A. Lebedeva, V. A. Bankole, Z. А. Abashidze, O. V. Aleinikova, Yu. V. Olshanskaya, E. A. Zerkalenkova, M. V. Gaskova, et al.

    In the past decades, significant advancements have been made in the treatment of children with acute myeloid leukemia (AML) with the introduction of more effective treatment regimens, extended indications for hematopoietic stem cell transplantation as well as better supportive therapy and prophylaxis of infectious complications. Nevertheless, an improvement in treatment outcomes is still an important goal. One of the key ways to enhance treatment effectiveness is risk stratification of AML patients based on molecular and genetic characteristics of the disease. A multicenter treatment protocol (the AML-MRD-2018 protocol) was developed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Our study includes 525 patients from 54 Russian hospitals who underwent treatment from November 2018 to December 2023. A total of 205 patients with a median age of 8.9 years (1 month – 17.6 years) were re-stratified to the intermediate-risk group. The 3-year overall and event-free survival for this group was 77% and 47%, respectively. The patients with biallelic CEBPA (dCEBPA) mutations had the most favorable prognosis. In the intermediate-risk group, early death before remission occurred in 6% of the patients; 8% of the patients died in first remission. Death of progressive disease occurred in 32% of all the deceased patients. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation.


  • Open Access

    Outcomes of treatment of childhood acute promyelocytic leukemia according to the APL 2003/2008 protocols in Russia and Belarus

    by O. V. Aleinikova, M. N. Sadovskaya, D. D. Baydildina, A. M. Popov, E. A. Zerkalenkova, Yu. V. Olshanskaya, E. A. Rudkova, M. E. Dubrovina, K. A. Voronin, E. V. Samochatova, et al.

    This study presents the results of treatment of 339 patients with acute promyelocytic leukemia (APL) from 57 regions of the Russian Federation (RF) and the Republic of Belarus (RB) according to the 2003/2008 APL treatment protocols, from 2008 to 1 January 2024. Based on the data from the AML-MRD-2018 protocol, the proportion of APL among childhood acute myeloid leukemia (AML) cases in the RF was investigated. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. It was established that the APL cases comprised 26% of AML cases, and APL incidence rate varied across the regions of the RF. Our findings suggest that the incidence of APL in Russian children is higher than in children from Europe and the USA, but further epidemiological research is needed to confirm this. The 5-year overall (OS) and event-free (EFS) survival rates in the patients treated according to the 2003/2008 APL protocols were 82% (95% confidence interval (CI) 78–86) and 73% (95% CI 67–78), respectively. In the low-risk group (LRG) the five-year OS and EFS rates were statistically significantly higher than in the high-risk group (HRG), with 5-year OS reaching 93% (95% CI 89–97) in the LRG and 63% (95% CI 55–72) (p 0.001) in the HRG, and EFS – 85% (95% CI 79–91) and 52% (95% CI 44–63) (p 0.001), respectively. The risk of relapse was higher in the HRG: 15% (95% CI 9.1–25) in the HRG vs 8.7% (95% CI 4.9–15%) in the LRG (p 0.045). The difference in the survival rates in the LRG and HRG was attributable to a higher mortality rate during remission induction in the HRG as compared to the LRG: 30.1% and 2.9%, respectively. Notably, 83.7% of deaths were caused by brain haemorrhage. Decreasing early death rate is key to improving APL treatment results in children in the RF and RB.

  • Open Access

    Acute myeloid leukemia with translocations involving the KMT2A gene in twins as a model for the study of leukemogenesis: clinical case reports and genetic characteristics

    by Z. Z. Askerova, E. A. Zerkalenkova, S. A. Lebedeva, K. S. Iskakova, D. A. Venyov, U. N. Petrova, D. D. Baydildina, D. N. Balashov, G. O. Bronin, I. Ya. Tomilin, et al.

    Familial cases of acute leukemia in children are very rare and are mainly reported in cases of genetically determined predisposition syndromes (mutations in the RUNX1, ETV6, ANKRD26, GATA2, SAMD9/SAMD9L, CEBPA genes) which have been well characterized in the last 15 years. In twins, leukemia is even more rare and is of particular interest for the study of leukemogenesis patterns and evolution of leukemic subclones. Here, we report about three pairs of twins: in one pair, KMT2A-r-leukemia was diagnosed simultaneously, while in the other two cases the second child remained healthy despite the development of KMT2A-r-leukemia in their twin. The patients’ parents gave consent to the use of their children's data, including photographs, for research purposes and in publications.

  • Open Access

    ОМЛ с транслокациями, вовлекающими ген КМТ2А, у близнецов как модель для исследования лейкемогенеза: описание клинических случаев и генетические характеристики.

    by Захра Зауровна Аскерова, Елена Александровна Зеркаленкова, Светлана Александровна Лебедева, Кристина Станиславовна Искакова, Дмитрий Александрович Венёв, Ульяна Николаевна Петрова, Дина Дамировна Байдильдина, Дмитрий Николаевич Балашов, Глеб Олегович Бронин, Иван Яковлевич Томилин, et al.

    Pediatric Hematology/Oncology and Immunopathology | Peer-rewiev medical journal Вопросы гематологии/онкологии и иммунопатологии в педиатрии | Научный рецензируемый журнал

  • Open Access

    The prognostic significance of partner genes and breakpoint locations in children with KMT2A-rearranged acute myeloid leukemia

    by S. A. Lebedeva, I. I. Kalinina, Yu. V. Olshanskaya, A. N. Kazakova, V. A. Bankole, M. S. Vasileva, D. A. Venyov, D. D. Baydildina, O. V. Aleinikova, A. V. Popa, et al.

    Acute myeloid leukemia (AML) with KMT2A rearrangements is one of the most common AML subtypes in children. KMT2A rearrangements are extremely heterogeneous because of different breakpoint locations in the DNA of this gene in combination with a large number of various partner genes. Patients with KMT2A-rearranged AML are typically stratified into a high-risk group. However, there are reports of different prognostic significance of different rearrangements of this gene found both in Russian and international literature. For example, several studies including both adults and children suggested that AML with t(1;11)(q21;q23.3)/KMT2A::MLLT1 and t(9;11)(q21;q23.3)/KMT2A::MLLT3 translocations had a more favorable prognosis. However, these findings failed to be reproduced in other studies. What is more, a number of studies stated that the prognosis of survival in patients aged 0–24 months affected by KMT2A-rearranged acute leukemia may depend not only on the partner gene but also on the location of a breakpoint in the KMT2A gene, while also saying that patients with a breakpoint in intron 11 have the worst prognosis. Here, we aimed to evaluate the prognostic significance of KMT2A rearrangements in children with AML. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of Russia. We concluded that specific partner gene and breakpoint location did not have any significant influence on treatment outcomes in children with KMT2A-rearranged AML who had been treated according to the AML-MRD-2018 protocol. These findings may indicate that such patients should be stratified into a high-risk group irrespective of the involved partner gene and breakpoint location.